基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02616 基石药业-B

未开盘 09-03 16:08:21

6.180

+0.000

0.00%

最高6.350	最低6.015	成交量558.93万
今开6.280	昨收6.180	日振幅5.42%
总市值98.63亿	流通市值98.63亿	总股本15.96亿
成交额3,438万	换手率0.35%	流通股本15.96亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02616","market":"HK","secType":"STK","nameCN":"基石药业-B","latestPrice":6.18,"timestamp":1788422901004,"preClose":6.18,"halted":0,"volume":5589302,"delay":0,"changeRate":0,"floatShares":1596000000,"shares":1596000000,"eps":-0.314752,"marketStatus":"未开盘","change":0,"latestTime":"09-03 16:08:21","open":6.28,"high":6.35,"low":6.015,"amount":34376404,"amplitude":0.054207,"askPrice":6.18,"askSize":8500,"bidPrice":6.17,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.302,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788485400000},"marketStatusCode":0,"adr":0,"listingDate":1551110400000,"exchange":"SEHK","adjPreClose":6.18,"openAndCloseTimeList":[[1788399000000,1788408000000],[1788411600000,1788422400000]],"volumeRatio":0.5755426989999497,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02616","defaultTab":"news","newsList":[{"id":"2664893277","title":"港股异动 | 基石药业-B(02616)早盘涨超4% 普拉替尼纳入医保后销售放量 上半年收入激增超3倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2664893277","media":"智通财经","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664893277?lang=zh_cn&edition=full","pubTime":"2026-09-02 11:42","pubTimestamp":1788320549,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B早盘涨超4%。消息面上，基石药业发布中期业绩，上半年收入2.05亿元人民币，同比增加314.75%。其中药品销售收入1.83亿元，主要来自普拉替尼、阿伐替尼和舒格利单抗。普拉替尼自2026年1月纳入国家医保目录后，截至2026年7月院内销售额同比增长近500%，成为收入增长的主要驱动力。恒生综合指数变动将于9月4日收市后实施并于9月7日起生效，届时沪深交易所会相应调整港股通可投资标的范围。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","02616","BK1574","KCAI","BK4585","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662704651","title":"基石药业-B(02616)发布中期业绩，收入2.05亿元 同比大幅增长314.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662704651","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662704651?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:39","pubTimestamp":1787830749,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布截至2026年6月30日止6个月的中期业绩，该集团取得收入人民币2.05亿元，同比增加314.75%;期内亏损2.52亿元，同比减少6.62%;每股亏损0.17元。公告称，收入包括药品销售1.83亿元、授权费收入690万元及舒格利单抗特许权使用费收入 1500万元。收入的大幅增长主要由药品的销售额显著增加所带动，此乃由于该药物自2026年1月起成功纳入国家医保药品目录，从而带动销量显著上升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109600233","title":"基石药业-B(02616)2026年上半年营收2.05亿元，经调整净亏损2.31亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1109600233","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109600233?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:36","pubTimestamp":1787830614,"startTime":"0","endTime":"0","summary":"基石药业-B发布的财报显示，2026年上半年实现营收2.05亿元，较上年同期的0.49亿元同比增长315.20%。经调整后的净亏损为2.31亿元，相比去年同期的2.65亿元亏损缩小约0.34亿元。成本方面，研发开支为2.06亿元，同比上升约95.30%，主要系CS2009等相关临床试验及早期研发投入加大。行政开支为0.51亿元，同比增长17.90%，主要由于人员成本增加所致。财报显示，在本期2.05亿元营收中，药品销售贡献1.83亿元，授权费收入约0.07亿元，特许权使用费约0.15亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"基石药业-B(02616)2026年上半年营收2.05亿元，经调整净亏损2.31亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662729977","title":"【券商聚焦】国投证券：创新药有望开启新一轮高景气周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2662729977","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662729977?lang=zh_cn&edition=full","pubTime":"2026-08-27 09:29","pubTimestamp":1787794154,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国投证券研究指，医药景气新周期背景下，国内创新药产业链加速崛起。近年国家多举措全链条支持创新药发展，叠加国内得天独厚的人才储备和研发效率等多维优势，国内创新药持续加速崛起且逐步具备全球竞争力。与此同时，海外MNC陆续面临专利悬崖困境，对外采购和扩充创新管线需求与日俱增，国内创新药企顺势而为，以海外授权BD等形式实现创新出海，创新药有望开启新一轮高景气周期。风险提示：产品研发及审批速度低于预期；产品降价超预期风险；海外BD授权不及预期风险；计算及假设不及预期风险。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989630","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","LU1226287875.USD","LU1813983027.USD","02142","01801","LU2242644610.SGD","KURE","LU1794554557.SGD","159992","SG9999002562.SGD","LU0348767384.USD","LU0359201612.USD","LU0516423091.SGD","KCE","LU0307460666.USD","LU0455707207.USD","LNGR","LU0039217434.USD","09688","06160","LU0880133367.SGD","01877","LU0348783233.USD","09995","02616","LU1770034418.SGD","BK1589","06185","LU0348825331.USD","IE0008369823.USD","161027","LU0326950275.SGD","LU0463099449.HKD","02269","LU0634319403.HKD","LU0314109678.HKD","01093","LU0051755006.USD","LU0417516738.SGD","09926","06978","IBBQ","LU1969619763.USD","LU1807302812.USD","SG9999004220.SGD","MEDX","LU0516422952.EUR","LU0140636845.USD","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662869747","title":"港股异动 | 基石药业-B(02616.HK)涨超7% 公司有望成为港股通标的 CS5007的IND申请获中国NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2662869747","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662869747?lang=zh_cn&edition=full","pubTime":"2026-08-25 13:51","pubTimestamp":1787637068,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02616","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661244437","title":"【券商聚焦】交银国际：中国内地mRNA疫苗产业整体低估严重","url":"https://stock-news.laohu8.com/highlight/detail?id=2661244437","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661244437?lang=zh_cn&edition=full","pubTime":"2026-08-24 09:18","pubTimestamp":1787534313,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，Moderna与默沙东共同宣布，intismeran联合K药辅助治疗IIB-IV期黑色素瘤的III期INTerpath-001研究达主要终点 。该机构认为，中国内地mRNA疫苗企业正处于全球公共卫生事件后的低谷期，产业整体低估严重，但海外可比产品的研发成功和适应症领域的拓展有望推动投资情绪和估值修复。此外，康希诺、智飞生物/沃森生物/康华生物等布局mRNA技术、处于估值底部的疫苗企业也值得持续关注。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989096","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03329","09995","LU1688375341.USD","LU1794554557.SGD","09688","MRNX","BK1589","09926","LU0307460666.USD","LU0181495838.USD","KURE","LU0880133367.SGD","02616","LU0244354667.USD","LU0417516571.SGD","LU0828237510.HKD","LU1303224171.USD","LU1960683339.HKD","LU0516422366.SGD","LU2097828557.USD","BK1147","06185","01093","LU0516423174.USD","SG9999002562.SGD","LU0979878070.USD","LU2488822045.USD","LU0067412154.USD","LU0588546209.SGD","01801","BK1576","LU1226287792.SGD","LU1242518931.SGD","MRNY","06160","LU0320764599.SGD","LU0348767384.USD","KCE","LU0348766576.USD","LU0043850808.USD","LU0561508036.HKD","LU0359201612.USD","02269","02142","01177","BK1191","01877","LU1008478684.HKD","LU0228659784.USD","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661262112","title":"基石药业-B(02616.HK)获纳入恒生综合指数 有望成为港股通标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2661262112","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661262112?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:49","pubTimestamp":1787309391,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02616","BK1161","HSCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180589068","title":"基石药业-B7月股份变动月报：股本降至15.96亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1180589068","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180589068?lang=zh_cn&edition=full","pubTime":"2026-08-06 18:10","pubTimestamp":1786011051,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年8月6日发布2026年7月股份变动月报表。报告期截至2026年7月31日，公司注册股本维持在2,000,000,000股，面值每股USD0.0001，总注册股本为USD200,000，较上期无变动。本月已发行股份由上月底的1,600,749,183股减少至1,596,276,652股，净减少4,472,531股。截至7月底，公司在港交所上市流通的普通股总数降至1,596,276,652股，并确认符合香港联交所《上市规则》有关公众持股比例的要求。基石药业-B同时声明，上述股份发行及购回事项均严格遵循相关上市规则与法律、监管要求办理。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139685448","title":"基石药业-B(02616)董事会拟于8月27日审议2026年中期业绩及分红事项","url":"https://stock-news.laohu8.com/highlight/detail?id=1139685448","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139685448?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:11","pubTimestamp":1786007485,"startTime":"0","endTime":"0","summary":"基石药业-B(02616)8月6日公告，公司董事会将于2026年8月27日（星期四）召开会议，主要议程包括：一、审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩及其发布；二、考虑派发中期股息（如有）。截至公告日，董事会成员包括主席兼非执行董事李伟博士、执行董事杨建新博士、非执行董事Kenneth Walton Hitchner III先生及胡正国先生，以及独立非执行董事Kenneth Howard Jarrett先生、谢芳女士和严嘉洵女士。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655832649","title":"【券商聚焦】国泰海通证券：全球多肽CDMO进入产能扩张周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655832649","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655832649?lang=zh_cn&edition=full","pubTime":"2026-07-29 09:21","pubTimestamp":1785288070,"startTime":"0","endTime":"0","summary":"国内外的多肽CDMO公司均加大对于产能的投资建设，尤其注重从临床前到商业化生产的一站式服务能力建设。2026年4月，凯莱英医药与天津经开区管委会签署合作备忘录，在天津经开区持续扩建化学大分子创新药CDMO研发生产基地，预计投资规模达20亿元人民币。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986985","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU0979878070.USD","161027","LU2476274308.USD","HK0000165453.HKD","01801","LU0348784397.USD","KCE","01093","BK1574","LU0307460666.USD","LU1719994722.HKD","09688","LU0181495838.USD","LU0417516738.SGD","LU0588546209.SGD","02611","BK1147","BK1588","IE00B5MMRT66.SGD","601211","BK1141","LU0052750758.USD","LU1008478684.HKD","02269","BK1583","BK1610","09926","IE00B0JY6N72.USD","LU2242644610.SGD","CDMO","02616","09995","06160","02142","LU0067412154.USD","SG9999002463.SGD","01877","LU1720050803.USD","06185","LU1251922891.USD","LU1328277881.USD","KURE","LU0634319403.HKD","IE00B543WZ88.USD","LU0359202008.SGD","LU0051755006.USD","BK1564","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167498784","title":"基石药业宣布管理层六月购入240万股，并计划2026年底启动CS2009全球三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1167498784","media":"投资观察","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167498784?lang=zh_cn&edition=full","pubTime":"2026-07-23 09:53","pubTimestamp":1784771619,"startTime":"0","endTime":"0","summary":"基石药业-B  于7月23日发布重要动态。公司宣布，其董事及高级管理层已于2026年6月期间，在公开市场购入总计240万股公司股份。此举彰显了管理层对公司未来发展的坚定信心与长期承诺。与此同时，公司披露了其核心在研产品CS2009的研发进展。基石药业计划于2026年底前，正式启动针对CS2009的全球多中心三期临床试验。投资者通常将此类内部人士购入股份视为对公司价值认可的重要指标，结合CS2009的研发里程碑，共同勾勒出公司未来的成长路径。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653791938","title":"基石药业-B(02616)获执行董事杨建新及高管增持242.05万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653791938","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653791938?lang=zh_cn&edition=full","pubTime":"2026-07-23 06:36","pubTimestamp":1784759789,"startTime":"0","endTime":"0","summary":"自2022年8月担任首席执行官以来，杨博士已于公开市场累计购买合共1371.45万股股份。该等股份增持后，截止本公告日期，杨博士持有合共相当于本公司已发行股本总额约5.26%的股份。杨博士、其他董事及高级管理层表示，彼等对本公司自身研发成果、商业化进展与长期业务发展充满信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02616","BK1574","SURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198818194","title":"基石药业-B高管6月再增持242.05万股，公司同期回购459.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1198818194","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198818194?lang=zh_cn&edition=full","pubTime":"2026-07-23 06:21","pubTimestamp":1784758862,"startTime":"0","endTime":"0","summary":"2026年7月23日，基石药业-B发布自愿性公告称，公司首席执行官、研发总裁兼执行董事杨建新博士联合其他董事及若干高管，于2026年6月在公开市场合计增持公司股份2,420,500股。公告显示，自2022年8月出任首席执行官以来，杨建新博士已在公开市场累计购入13,714,500股。截至公告披露日，其持股数量约占公司已发行股本总额的5.26%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652638792","title":"基石药业-B(02616)：ESMO 2026预告-更多临床数据进一步验证 CS2009(PD-1/VEGF/CTLA-4三特异性抗体)临床潜力与全球开发前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2652638792","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652638792?lang=zh_cn&edition=full","pubTime":"2026-07-20 08:06","pubTimestamp":1784505987,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，公司核心资产之一CS2009(PD-1/VEGF/CTLA-4三特异性抗体)的临床研究成果成功入选2026年欧洲肿瘤内科学会(ESMO)年会，并将以两项快速口头报告的形式呈现，分别涵盖CS2009在晚期非小细胞肺癌(NSCLC)以及转移性结直肠癌(mCRC)患者中的I/II期临床试验数据。目前，相关摘要标题已在ESMO官网公布。需说明的是，摘要中所呈现的数据仅截至2026年4月，旨在符合大会递交期限之要求。基石药业将于2026年10月23日至26日在西班牙马德里召开的ESMO年会现场，展示数据截止日期更临近会议时间的临床研究结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","LU1169590202.USD","PD","BK4023","BK1161","BK1574","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128500850","title":"基石药业-B核心资产CS2009两项临床数据入选ESMO 2026年会","url":"https://stock-news.laohu8.com/highlight/detail?id=1128500850","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128500850?lang=zh_cn&edition=full","pubTime":"2026-07-20 08:05","pubTimestamp":1784505935,"startTime":"0","endTime":"0","summary":"2026年7月20日，基石药业-B发布自愿公告称，其核心产品CS2009在晚期非小细胞肺癌和转移性结直肠癌患者中的I/II期临床研究成果，获2026年欧洲肿瘤内科学会年会收录，并将以两场快速口头报告形式对外公布。ESMO年会将于2026年10月23日至26日在西班牙马德里举行。基石药业-B表示，届时将公布截至会前最新的数据；公告中的摘要信息仅统计到2026年4月，以满足会议提交时间要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651991128","title":"【券商聚焦】中信证券：新基药目录有望加速创新药基层落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2651991128","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651991128?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:57","pubTimestamp":1783990650,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，《2026年版国家基本药物目录》于7月9日正式发布，将于9月1日起实施。该机构认为，本次新版基药目录新增药物均已属于医保药品，随着基药与医保的深度协同联动，有望极大加速创新药的基层落地，医保控费与创新回报形成良性循环。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985769","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","LU1960683339.HKD","LU0314109678.HKD","LU1226288253.USD","LU0979878070.USD","159992","09688","LU0051755006.USD","06185","01093","LU0359201612.USD","02616","LU1961090484.USD","MEDX","01177","LU1242518931.SGD","LU1226287792.SGD","06978","02269","HK0000165453.HKD","LU2328871848.SGD","LU2476274720.SGD","BK1500","LU0405327494.USD","LU1328277881.USD","09995","KCE","LU0823426480.USD","BK1610","LU1152091168.USD","02142","01877","LU0417516902.SGD","06030","LU2039709279.SGD","KURE","LU0572944931.SGD","SG9999002463.SGD","IBBQ","600030","09926","LU0043850808.USD","IE00BPRC5H50.USD","LU1997244956.HKD","BK1161","LU2488822045.USD","06160","IE0008368742.USD","LU0588546209.SGD","LU0327786744.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651568164","title":"【券商聚焦】中信建投：创新药企仍是高增长主线、BD交易持续催化业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2651568164","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651568164?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:53","pubTimestamp":1783903985,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，1）制药产业链：创新药企仍是高增长主线，BD交易持续催化业绩。BD授权收入成为多家公司中期业绩关键变量。上游供应链受益于国产替代及下游需求恢复，Q2增速普遍提升，利润端弹性显著。建议关注Q2高增长公司的配置机会。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985645","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1960683339.HKD","LU0455707207.USD","01801","LU0051755006.USD","KURE","LU2097828631.EUR","LU0067412154.USD","MEDX","LU0348825331.USD","601066","02616","LU0359202008.SGD","LU2242644610.SGD","02269","BD","LU1969619763.USD","LU1688375341.USD","LU0501845795.SGD","09926","LU0516422366.SGD","KCE","LU0456846285.SGD","LU2488822045.USD","LU0359201612.USD","06160","BK1588","159992","IE00B0JY6N72.USD","06978","LU1226288170.HKD","LU2097828474.EUR","06185","01877","IE00B5MMRT66.SGD","09688","LU1807302812.USD","01177","LU0348735423.USD","BK1515","LU0348784397.USD","LU1961090484.USD","01093","IBBQ","LU1993786604.SGD","LU1813983027.USD","BK1161","09995","02142","IE0008368742.USD","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118022467","title":"基石药业-B更新6月股份变动月报表，已发行股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1118022467","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118022467?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:43","pubTimestamp":1783421001,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年7月7日公布了截至2026年6月30日的证券变动月报，显示公司当月无新增股份发行或注销，已发行及注册股本均保持不变。报告期内，公司已发行普通股总数为1,600,749,183股，库存股份数为0股，继续满足香港联合交易所有限公司的公众持股量要求。根据公告，基石药业-B法定/注册股本为2,000,000,000股普通股，每股面值USD 0.0001，法定/注册股本总额USD 200,000，与上月底保持一致。本次公告由公司董事李伟签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648634520","title":"【券商聚焦】中信建投：看好相关创新药及制药企业医保准入与商保增量空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2648634520","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648634520?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:36","pubTimestamp":1783038993,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投研究指，2026年6月29日，国家医保局公示通过2026年基本医保目录及商保创新药目录调整初步形式审查的药品名单及相关信息。叠加今年首次引入的“预申报”机制，本次结果充分体现了医保目录调整对创新药的持续倾斜，看好相关创新药及制药企业的医保准入与商保增量空间。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985028","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0501845795.SGD","LU0315179316.USD","LU1688375341.USD","159992","LU1226287875.USD","LU0502904849.HKD","LU0456846285.SGD","HK0000165453.HKD","09926","601066","02269","LU0979878070.USD","09688","IE0008369823.USD","01877","LU0043850808.USD","01801","LU0417516902.SGD","LU2097828631.EUR","01477","LU2039709279.SGD","06978","LU0516422366.SGD","01177","SG9999004220.SGD","LU3063872942.SGD","06185","LU0417516738.SGD","01093","IE00B031HY20.USD","LU2097828714.EUR","LU2778985437.USD","06160","LU1226287792.SGD","09995","IE00B5MMRT66.SGD","LU1961090484.USD","LU2476274720.SGD","LU0348766576.USD","LU0072913022.USD","02616","LU0067412154.USD","LU0856984785.SGD","LU1242518931.SGD","LU2476274308.USD","LU2488822045.USD","02142","LU1969619763.USD","LU2097828805.USD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647453054?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["03388","00068","09637","02272","01672","02335","02672","01286","01081","01392","02553","01779","02729","02526","06636","01021","02670","06675","07688","03310","03625","02632","06938","00600","01609","00412","06106","06656","BK4585","01440","02723","09630","03355","02616","01866","00340","01133","01879","BK4588","02142","00100","07666","00863","06872","01191","02726","01236","06658","01651","03277","02696","03661","01956","07630","00376","03887","01511"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.cstonepharma.com","stockEarnings":[{"period":"1week","weight":-0.0298},{"period":"1month","weight":0.3657},{"period":"3month","weight":0.3149},{"period":"6month","weight":-0.0707},{"period":"1year","weight":-0.4893},{"period":"ytd","weight":0.1727}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0247},{"period":"3month","weight":0.0101},{"period":"6month","weight":-0.0211},{"period":"1year","weight":-0.0051},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"基石药业是一家主要从事肿瘤、自身免疫和炎症及其他关键疾病领域药物研发及销售的投资控股公司。该公司通过子公司主要从事生物制药产品的研发、药品的销售及提供其知识产权（IP）授权或商业化授权。该公司产品主要包括精准治疗药物“泰吉华”（阿伐替尼）及“普吉华”（普拉替尼）、以及“择捷美”（舒格利单抗）等。该公司还从事肿瘤免疫药物的开发及商业化。该公司主要在中国国内市场、以及中欧、东欧和瑞士等海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.050688},{"month":2,"riseRate":0.428571,"avgChangeRate":0.069097},{"month":3,"riseRate":0.25,"avgChangeRate":-0.053883},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.031371},{"month":5,"riseRate":0.428571,"avgChangeRate":0.066954},{"month":6,"riseRate":0.625,"avgChangeRate":0.030763},{"month":7,"riseRate":0.5,"avgChangeRate":0.038991},{"month":8,"riseRate":0.5,"avgChangeRate":0.110606},{"month":9,"riseRate":0.5,"avgChangeRate":-0.052781},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.012196},{"month":11,"riseRate":0.571429,"avgChangeRate":0.010396},{"month":12,"riseRate":0.428571,"avgChangeRate":0.004524}],"exchange":"SEHK","name":"基石药业-B","nameEN":"CSTONE PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"基石药业-B,02616,基石药业-B股票,基石药业-B股票老虎,基石药业-B股票老虎国际,基石药业-B行情,基石药业-B股票行情,基石药业-B股价,基石药业-B股市,基石药业-B股票价格,基石药业-B股票交易,基石药业-B股票购买,基石药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}